suggesting that electrical cardioversion in patients treated with these agents has a low thromboembolic risk that is comparable to warfarin (3) (4) (5) (6) . None of these trials had detection of left atrial appendage thrombus on transesophageal echocardiography (TEE) as an endpoint. These strategies have been adapted to patients undergoing ablation for atrial fibrillation. The management of anticoagulation therapy before and at the time of the ablation procedure has progressed from withholding to continuing these oral agents as the experience in centers performing ablation has resulted in improved safety profiles (7) .
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